No Data
IMMUNOTECH-B (06978) has not yet submitted any new drug application for EAL and plans to submit it in the near future.
IMMUNOTECH-B (06978) issued an announcement stating that based on the recent cooperation with the National Medical Products Administration of China (NMP...
Express News | Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Featured announcements | Kanzhun revenue increased 19% year-on-year in the third quarter; China Taibao's original premium income during the year exceeded 410 billion yuan
Xinyi Glass and Xinyi Auto Glass (Hong Kong) signed a 2024 glass supply agreement; CGN Energy completed a cumulative total of 17,684.1 gigawatt-hours of power generation in the first 11 months, an increase of 1.7% over the previous year.
IMMUNOTECH-B (06978.HK): CAR-T-19 injection has been granted breakthrough therapy designation.
On December 11, Gelonghui announced that IMMUNOTECH-B (06978.HK) has released a statement indicating that the group's product CAR-T–19 injection (a type of anti-CD19 single-chain antibody chimeric antigen receptor T cell injection) has been granted breakthrough therapy designation by the National Medical Products Administration's Drug Evaluation Center for the treatment of patients aged 25 and younger with relapsed/refractory B-cell acute lymphoblastic leukemia ("B-ALL"). This designation is based on reliable clinical efficacy and safety data for CAR-T–19 injection. It will expedite the clinical development of CAR-T–19 injection and accelerate its availability for patients.
